Patrick Roberts, Incyclix Bio CEO

Cosela mak­er's ear­ly em­ploy­ees aim to repli­cate 'blue­print' at a new biotech — with an old G1 as­set

Three of the ear­li­est em­ploy­ees at G1 Ther­a­peu­tics want to re­peat the blue­print they laid at se­cur­ing ap­proval for CDK4/6 in­hibitor Cosela by tak­ing a …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.